AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26035186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 26035186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (both doses)
Number of subjects: 469
Study 23857320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 2368
Study 21539650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (calories in the range of BEE × 1.1 × 1.3 to 1.5, 37.9 ± 6.5 kcal/kg/day)
Number of subjects: 60
Study 21539650 — intervention group
Group type: COMPARATOR
Intervention: Control group (29.1 ± 4.9 kcal/kg/day)
Number of subjects: 60
Study 19179714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling
Number of subjects: 84
Study 19179714 — intervention group
Group type: COMPARATOR
Intervention: No sling
Number of subjects: 84
Study 17557449 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 17557449 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 0
Study 15196362 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary duct closure
Number of subjects: 55
Study 15196362 — intervention group
Group type: COMPARATOR
Intervention: T‐tube drainage
Number of subjects: 55
Study 11438132 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg for 14 days
Number of subjects: 100
Study 11438132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9872636 — intervention group
Group type: EXPERIMENTAL
Intervention: Burke and Bowden chart
Number of subjects: 20
Study 9872636 — intervention group
Group type: COMPARATOR
Intervention: Oakley chart
Number of subjects: 20
Study 8577634 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐caffeine breath test (C3BT)
Number of subjects: 20
Study 8577634 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐caffeine breath test (C7BT)
Number of subjects: 20
Study 8577634 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 2551355 — intervention group
Group type: COMPARATOR
Intervention: 2-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-4 and vincristine 1 mg i.v. days 1 + 4; every 4 weeks)
Number of subjects: 55
Study 2551355 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-3, vincristine 2 mg i.v. day 1 and 1 mg i.v. day 5, methotrexate 30 mg i.v. days 3 and 5, CCNU 80 mg/m2 i.v. day 2; every 7 weeks)
Number of subjects: 55
Study 2551355 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiotherapy (55 Gy/25 fractions/8 weeks)
Number of subjects: 55
Study 2551355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) 40 Gy/20 fractions/4 weeks
Number of subjects: 55
Study 332438 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin, 900 mg daily
Number of subjects: 18
Study 332438 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa, 2,250 mg daily
Number of subjects: 18
Study 332438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31587885 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg intravenously)
Number of subjects: 100
Study 31587885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27049354 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 120
Study 27049354 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride
Number of subjects: 120
Study 27049354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 26211623 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 26211623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23275404 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weekly doses of milieu communication teaching (MCT)
Number of subjects: 64
Study 23275404 — intervention group
Group type: COMPARATOR
Intervention: 1 weekly dose of milieu communication teaching (MCT)
Number of subjects: 64
Study 22024276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Lp‐PLA2 levels
Number of subjects: 40
Study 22024276 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque volume (PV)
Number of subjects: 40
Study 22024276 — intervention group
Group type: EXPERIMENTAL
Intervention: % change in PV
Number of subjects: 40
Study 22024276 — intervention group
Group type: EXPERIMENTAL
Intervention: % changes in Lp‐PLA2 and PV
Number of subjects: 40
Study 22024276 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute change in PV
Number of subjects: 40
Study 19517231 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix (HAV) vaccine
Number of subjects: 84
Study 19517231 — intervention group
Group type: EXPERIMENTAL
Intervention: TWINRIX (HAV/HBV combination vaccine)
Number of subjects: 84
Study 19517231 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix (HBV) vaccine
Number of subjects: 84
Study 19517231 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HAV/HBV vaccination
Number of subjects: 84
Study 17197592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine intracervical block
Number of subjects: 120
Study 17197592 — intervention group
Group type: COMPARATOR
Intervention: Intracervical saline injection
Number of subjects: 120
Study 17197592 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 120
Study 17197592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 120
Study 15851169 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine test
Number of subjects: 42
Study 11190900 — intervention group
Group type: EXPERIMENTAL
Intervention: G20210A prothrombin gene mutation prevalence in women with recurrent miscarriage
Number of subjects: 122
Study 11190900 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy parous women)
Number of subjects: 122
Study 11190900 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patient group
Number of subjects: 122
Study 11190900 — intervention group
Group type: COMPARATOR
Intervention: Caucasian control group
Number of subjects: 122
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =90 mm Hg
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =85 mm Hg
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =80 mm Hg
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 75 mg/day
Number of subjects: 18790
Study 9635947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group < or =80 mm Hg vs target group < or =90 mm Hg (in patients with diabetes mellitus)
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure at mean achieved 82.6 mm Hg
Number of subjects: 18790
Study 9635947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure at 86.5 mm Hg
Number of subjects: 18790
Study 8162627 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and Simvastatin 10 mg/day (CS)
Number of subjects: 33
Study 8162627 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and Bezafibrate 400 mg/day (CB)
Number of subjects: 33
Study 2735338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate tablets
Number of subjects: 75
Study 2735338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 75
Study 2735338 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study 4985836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Number of subjects: 11
Study 4985836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Number of subjects: 11
Study 4985836 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibodies comprised 7S gammaG immunoglobulins with a minor 19S gammaM component in about half the cases
Number of subjects: 11
Study 31033903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Reality (I-VR) during high-intensity cycling
Number of subjects: 94
Study 31033903 — intervention group
Group type: COMPARATOR
Intervention: Static VR/motor imagery control
Number of subjects: 94
Study 28167660 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 157
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 36
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% NaOCl
Number of subjects: 36
Study 25831102 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 36
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm without cariogenic challenge
Number of subjects: 36
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm with cariogenic challenge
Number of subjects: 36
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month water storage
Number of subjects: 36
Study 25831102 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h control
Number of subjects: 36
Study 23121681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 90
Study 23121681 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 90
Study 22420399 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaClose topical tissue expansion device
Number of subjects: 25
Study 22420399 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 25
Study 22420399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local full-thickness skin graft closure
Number of subjects: 25
Study 22420399 — intervention group
Group type: COMPARATOR
Intervention: Patient assessment of cosmesis
Number of subjects: 25
Study 22420399 — intervention group
Group type: COMPARATOR
Intervention: Michigan Hand Outcomes Questionnaire scores
Number of subjects: 25
Study 18753738 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally t.i.d.)
Number of subjects: 78
Study 18753738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 17994436 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, single 1 gram dose
Number of subjects: 1452
Study 17994436 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracycline, twice per day for six weeks
Number of subjects: 1452
Study 15487810 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg once daily
Number of subjects: 12
Study 15487810 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg every 12 hours
Number of subjects: 12
Study 15487810 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg once daily plus gemfibrozil 600 mg every 12 hours
Number of subjects: 12
Study 11571454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3x1 g/day for 14 days
Number of subjects: 60
Study 11571454 — intervention group
Group type: COMPARATOR
Intervention: No preemptive treatment (Control group)
Number of subjects: 60
Study 11571454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir 2x5 mg/kg body weight for 14 days (for those who developed CMV disease)
Number of subjects: 60
Study 9804594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration (0.4 mg/kg)
Number of subjects: 5
Study 9804594 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study 7822675 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Disposable Wear (DDW)
Number of subjects: 195
Study 7822675 — intervention group
Group type: COMPARATOR
Intervention: Conventional Daily Wear (CDW)
Number of subjects: 195
Study 3361417 — intervention group
Group type: EXPERIMENTAL
Intervention: Value self-confrontation
Number of subjects: 87
Study 3361417 — intervention group
Group type: COMPARATOR
Intervention: Group discussion
Number of subjects: 87
Study 3361417 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 87
Study 31711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in BMI (2.5-4.9%)
Number of subjects: 81388
Study 31711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in BMI (5.0-9.9%)
Number of subjects: 81388
Study 31711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in BMI (10.0-14.9%)
Number of subjects: 81388
Study 31711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in BMI (≥ 15.0%)
Number of subjects: 81388
Study 31711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 5% decrease in BMI
Number of subjects: 81388
Study 31711465 — intervention group
Group type: COMPARATOR
Intervention: Stable BMI
Number of subjects: 81388
Study 30334914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader flap with triangular spreader graft (group 3)
Number of subjects: 36
Study 30334914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader flap with rectangular spreader graft (group 2)
Number of subjects: 36
Study 30334914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader flap (group 1)
Number of subjects: 36
Study 26865198 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (cumulative medication adherence, ≥80%)
Number of subjects: 33728
Study 26865198 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence (cumulative medication adherence, <50%)
Number of subjects: 33728
Study 26865198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate adherence (cumulative medication adherence, 50%-80%)
Number of subjects: 33728
Study 26865198 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor medication adherence
Number of subjects: 33728
Study 25190615 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral potassium replacement (EPR)
Number of subjects: 0
Study 25190615 — intervention group
Group type: COMPARATOR
Intervention: Intravenous potassium replacement (IVPR)
Number of subjects: 0
Study 21979104 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 21979104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 21979104 — intervention group
Group type: COMPARATOR
Intervention: Both Propofol and Sevoflurane
Number of subjects: 40
Study 19046051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine showers
Number of subjects: 0
Study 19046051 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorhexidine showers)
Number of subjects: 0
Study 17218552 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium
Number of subjects: 1829
Study 15367512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 1658
Study 15367512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1658
Study 11211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 22
Study 11211063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9554820 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO (2000 U/twice weekly)
Number of subjects: 84
Study 9554820 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO (3000 U twice weekly after 6 weeks if Hb increase was below 1 g%)
Number of subjects: 84
Study 9554820 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO therapy
Number of subjects: 84
Study 8060471 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin and prednisolone (double therapy)
Number of subjects: 195
Study 8060471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin, prednisolone, and azathioprine (triple therapy)
Number of subjects: 195
Study 3137765 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 3137765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30920593 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET
Number of subjects: 635
Study 30920593 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-directed focal therapy
Number of subjects: 635
Study 28633774 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (NIN)
Number of subjects: 104
Study 28633774 — intervention group
Group type: COMPARATOR
Intervention: Electric shockwave therapy
Number of subjects: 104
Study 25196721 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm ergometer exercise training
Number of subjects: 24
Study 25196721 — intervention group
Group type: COMPARATOR
Intervention: Strengthening range-of-motion (ROM) exercise program
Number of subjects: 24
Study 24111257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low workload (WKL) condition
Number of subjects: 20
Study 24111257 — intervention group
Group type: EXPERIMENTAL
Intervention: High workload (WKL) condition
Number of subjects: 20
Study 24111257 — intervention group
Group type: EXPERIMENTAL
Intervention: Short time on task (TOT) condition
Number of subjects: 20
Study 24111257 — intervention group
Group type: EXPERIMENTAL
Intervention: Long time on task (TOT) condition
Number of subjects: 20
Study 21438131 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZO) 125 mg/kg every 8 hr
Number of subjects: 49
Study 21438131 — intervention group
Group type: COMPARATOR
Intervention: Cefozopran (CZOP) 25 mg/kg every 6 hr
Number of subjects: 49
Study 21438131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PIP/TAZO and CZOP
Number of subjects: 49
Study 19569068 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI (high-dose tirofiban)
Number of subjects: 39
Study 19569068 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI (control)
Number of subjects: 39
Study 17826502 — intervention group
Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in virgin nondiabetic patients
Number of subjects: 467
Study 17826502 — intervention group
Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in virgin diabetic patients
Number of subjects: 467
Study 17826502 — intervention group
Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in revision patients without washout
Number of subjects: 467
Study 17826502 — intervention group
Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in revision patients with antiseptic washout
Number of subjects: 467
Study 17826502 — intervention group
Group type: COMPARATOR
Intervention: Noncoated IPPs (historical control)
Number of subjects: 467
Study 15571635 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mineral water
Number of subjects: 70
Study 15571635 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium enriched water
Number of subjects: 70
Study 15571635 — intervention group
Group type: COMPARATOR
Intervention: Water low in minerals
Number of subjects: 70
Study 11071026 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost, 50 microg/ml once daily
Number of subjects: 164
Study 11071026 — intervention group
Group type: COMPARATOR
Intervention: Timolol 5 mg/ml plus dorzolamide, 20 mg/ml twice daily
Number of subjects: 164
Study 9071196 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion therapy (within six hours)
Number of subjects: 301
Study 9071196 — intervention group
Group type: COMPARATOR
Intervention: Late reperfusion therapy (after six hours)
Number of subjects: 301
Study 8370002 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc (IVD) simulation before clinical experience (Group 1, n = 18)
Number of subjects: 39
Study 8370002 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical experience first (Group 2, n = 21)
Number of subjects: 39
Study 2425315 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone (1.0 mg in 10 mL preservative-free saline)
Number of subjects: 52
Study 2425315 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (10 mL of 0.25%)
Number of subjects: 52
Study 31525795 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 189
Study 31525795 — intervention group
Group type: COMPARATOR
Intervention: Cocktail of medications (CO)
Number of subjects: 189
Study 31931137 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 693
Study 28866140 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fruit and vegetable juice powder concentrate (JuicePlus+®)
Number of subjects: 183
Study 28866140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 27511740 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual standardized reminiscence therapy performed by trained nursing home volunteers
Number of subjects: 60
Study 27511740 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 24499473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher brand equity from the antidrug campaign
Number of subjects: 0
Study 22520526 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES-R)
Number of subjects: 51
Study 22520526 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 51
Study 20135251 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI diagnostics of TMJ
Number of subjects: 58
Study 18835314 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg retinol equivalent) alongside the pentavalent vaccine
Number of subjects: 0
Study 18835314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 0
Study 18835314 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with pentavalent vaccine
Number of subjects: 0
Study 16681880 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d
Number of subjects: 28
Study 16681880 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/d
Number of subjects: 28
Study 16681880 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 80 mg/d
Number of subjects: 28
Study 16681880 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d (HNPCC)
Number of subjects: 28
Study 12831221 — intervention group
Group type: EXPERIMENTAL
Intervention: Function regulator (FR)
Number of subjects: 18